A July 2026 commentary from Eira Research Fellow Kristina Acri challenges a recent analysis claiming that patents contribute to premature deaths among people with diabetes.
Read MoreIP
How patenting reliability influences R&D financing
In a new working paper, “Declining Patent Reliability and Venture Capital Reallocation,” Mark Schultz finds investment shifted away from patent-intensive sectors in the United States between 2004 to 2017.
Read MoreEira Conference October 2026: Competing for the Cure: Intellectual Property, Innovation Policy, and Biopharmaceutical Ecosystems
We are pleased to announce the upcoming conference hosted by the Eira Initiative in association with the Berkeley Policy Institute: Competing for the Cure: Intellectual Property, Innovation Policy, and Biopharmaceutical Ecosystems (October 29–30, 2026).
Read MoreEvergreening's Empirical Chasm: A Working Paper from the Eira Initiative
A working paper from the Eira Initiative examines data on pharmaceutical innovation. The author, Professor Erika Lietzan, finds that the evergreening narrative (which alleges companies patent revisions to drugs to prolong intellectual property protection) is conceptually flawed, misrepresents how patents and exclusivity intersect with drug approval frameworks, and risks misleading policymakers into enacting measures that would punish innovation to the detriment of patients.
Read MoreAI + Intellectual Capital + IP: New Challenges and Opportunities for Companies
in Strategy
Writing as a guest for The Intangible Investor column in IPWatchdog, David Teece examines the growing use of artificial intelligence, and its implications for the intellectual capital and intellectual property rights of firms.
Read More